Mar 8 2010
Ricerca
Biosciences, LLC, announced today the finalization of the
acquisition of the Discovery and Preclinical business of MDS
Pharma Services with facilities and almost 600 associates in
Bothell, Washington; Lyon, France; and Taipei, Taiwan.
“With facilities worldwide
combining local experience, immense scientific expertise and a strong
commitment to excellent client service, we provide unique discovery and
development services. Our expanded organization is a research partner
clients can rely on to think strategically about projects, anticipate
needs and rapidly deliver study results.”
The expanded organization provides the biopharmaceutical industry with
access to a global contract research organization (CRO) focused on the
developmental phase between intellectual property (IP) and submission of
the investigational new drug (IND) application. The increased capacity
and capabilities deliver numerous benefits, including:
-
Global toxicology allowing coordination of projects between North
America, Europe and Asia
-
Access to cGMP and non-GMP API synthesis and process development for
IND-enabling toxicology performed in North America and Europe
-
Expanded and enhanced DMPK services and efficacy models
-
Streamlined lead optimization service combining efficacy and biomarker
assays with medicinal chemistry
-
Complete pharmacological profiling services including molecular,
cellular, tissue and in vivo assays of development candidates
-
Radio labeled compound synthesis available for all locations worldwide
Ricerca Chairman and CEO Ian Lennox stated, “With facilities worldwide
combining local experience, immense scientific expertise and a strong
commitment to excellent client service, we provide unique discovery and
development services. Our expanded organization is a research partner
clients can rely on to think strategically about projects, anticipate
needs and rapidly deliver study results.”
Source Ricerca Biosciences
Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease